Increased spending for treatment of HIV patients does not necessarily lead to a more positive clinical outcome, according to a new study presented at the 2013 United States Conference on AIDS.
Researchers found that overall cognitive performance was below average in a sample of patients with HIV who were referred for neurocognitive evaluation. Especially affected were areas involving memory, which can have a negative effect on treatment adherence.
Study results presented at the 2013 United States Conference on AIDS show that both combo drugs have a similar efficacy profile in ART-naïve patients, but patients treated with Complera reported fewer and less severe side effects.
Recently released testing guidelines and expanded access to insurance coverage under the ACA may improve awareness and treatment among HIV-positive, economically underserved, and minority populations that are disproportionately impacted by viral hepatitis infection.